Loading Events

Purple Biotech Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24

Banners - 2024-06-24T123953.275
DATE: July 11, 2024
TIME: 10:30 AM EDT

About The Event

Join Purple Biotech for a virtual key opinion leader (KOL) event featuring Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD, FASCO (University of Washington School of Medicine, Fred Hutchinson Cancer Center), who will discuss the positive interim data from the Phase 2 study of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (PDAC).

The event will focus on data reported at the 2024 ASCO Annual Meeting demonstrated reduced risk of death and progression, prolongation of OS and progression free survival (PFS), higher objective response rate (ORR), disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+Nal-IRI/5FU/LV arm and the new exploratory biomarker data suggesting that baseline serum myeloperoxidase (MPO) may be a predictive biomarker for the treatment effect of CM24-nivolumab therapy on overall survival. CM24 is a humanized monoclonal antibody that blocks the interactions of CEACAM1, a protein expressed on tumor and immune cells, and is a part of the Neutrophils Extra Cellular Traps (NETs), involved in tumor immune evasion and survival through multiple pathways.

For more information, click here.

Management will discuss Purple Biotech plans for CM24.